Biondvax Pharmaceuticals Ltd., of Jerusalem, said the European Investment Bank has agreed to extend the 2017 financing agreement by an additional €4 million (US$4.5 million). The funds will be used in support of an ongoing pivotal, clinical efficacy, phase III trial of the company's M-001 universal flu vaccine candidate in Europe.